Extended Data Fig. 7: Extended characterization of ESO80BB TCR T cells in a subcutaneous melanoma model.
From: Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
a, Diagram depicting TCR T cell engineering. The alpha and beta chains of an NY-ESO-1 directed TCR were targeted into the TRAC locus as previously described34. 80BB was delivered using the SFG γ-retroviral vector. b, c, d, e, Analyses of T cells isolated from the tumours or spleens of mice implanted with subcutaneous SK-Mel-37 and treated with ESO-TCR or ESO-TCR80BB. n = 4 mice per group per time point b, CD4+ Tetramer+ T cell counts isolated from tumours or spleens. c, counts of CD8+Tetramer+ T stem cell memory (Tscm, CCR7+, CD45Ra+), CD8+Tetramer+ T central memory cells (Tcm, CCR7+, CD45Ra-), CD8+Tetramer+ T effector memory cells (Tem, CCR7-, CD45Ra-) CD8+Tetramer+ T effector cells (Teff, CCR7-, CD45Ra+) isolated from spleens. d, Percentage of Tetramer+ CD8+ spleen-isolated T cells expressing Granzyme B, IFNɣ, IL-2 TNF-a after PMA/Ionomycin stimulation. e, Frequency of Tetramer+ CD8+ spleen-isolated T cells expressing PD-1, Lag3, Tim3 or PD-1 and Tim3 double positive cells. P values were determined by two-tailed t-test (c, d, e). Data are mean ± sem.
